← back to search

Junya Fujimoto

The University of Texas MD Anderson Cancer Center · US
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Radiomics and Machine Learning in Medical Imaging, and RNA modifications and cancer.
h-index
83
citations
53,620
works
681
NIH funding
primary concept
Medicine
email

Recent publications

Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception
Cancer Cell 2025cited by 26position: middledoi
Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions
Cancer Cell 2025cited by 12position: middledoi
An atlas of epithelial cell states and plasticity in lung adenocarcinoma
Nature 2024cited by 155position: middledoi
Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma
Modern Pathology 2023cited by 32position: middledoi
Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study
Journal of Thoracic Oncology 2023cited by 27position: middledoi
Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers
Frontiers in Oncology 2023cited by 3position: middledoi
The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma
Cancer Discovery 2022cited by 152position: middledoi
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing
Cancer Discovery 2021cited by 128position: middledoi
Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer
Communications Biology 2021cited by 101position: middledoi
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
Clinical Cancer Research 2021cited by 75position: middledoi
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer
Nature Communications 2021cited by 50position: middledoi
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
Nature Cancer 2020cited by 369position: middledoi
Comprehensive T cell repertoire characterization of non-small cell lung cancer
Nature Communications 2020cited by 228position: middledoi
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity
Genome biology 2020cited by 63position: middledoi
Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development
American Journal of Respiratory and Critical Care Medicine 2020cited by 46position: middledoi
Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer
American Journal of Respiratory and Critical Care Medicine 2019cited by 35position: middledoi
Abstract A153: Targeting DNA damage response upregulates PD-L1 level and promotes antitumor immunity in small-cell lung cancer
Cancer Immunology Research 2019cited by 0position: middledoi
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Cancer Discovery 2018cited by 616position: middledoi
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
Journal of Clinical Oncology 2018cited by 396position: middledoi
The Integrated Genomic Landscape of Thymic Epithelial Tumors
Cancer Cell 2018cited by 381position: middledoi
Comprehensive analysis of lung cancer pathology images to discover tumor shape and boundary features that predict survival outcome
Scientific Reports 2018cited by 148position: middledoi
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
JAMA Oncology 2017cited by 755position: middledoi
Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma
Cancer Research 2017cited by 125position: middledoi
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies
Oncotarget 2017cited by 92position: middledoi
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
Annals of Oncology 2016cited by 209position: middledoi
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
Annals of Oncology 2016cited by 118position: middledoi
Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway
Cancer Research 2016cited by 50position: middledoi
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
Journal of Thoracic Oncology 2015cited by 427position: middledoi
ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers
Proceedings of the National Academy of Sciences 2014cited by 283position: middledoi
Transcriptomic Architecture of the Adjacent Airway Field Cancerization in Non–Small Cell Lung Cancer
JNCI Journal of the National Cancer Institute 2014cited by 85position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ignacio I. Wistuba · Disco (Germany)11 papers (2014–2020)John V. Heymach · 1The University of Texas MD Anderson Cancer Center7 papers (2016–2020)Jing Wang · IHS Markit (United States)5 papers (2017–2020)Neda Kalhor · The University of Texas MD Anderson Cancer Center5 papers (2014–2020)César A. Moran · The University of Texas MD Anderson Cancer Center5 papers (2014–2020)Humam Kadara · The University of Texas MD Anderson Cancer Center5 papers (2014–2019)Lauren A. Byers · The University of Texas MD Anderson Cancer Center5 papers (2017–2021)Carmen Behrens · University of Illinois Chicago4 papers (2014–2019)Stephen G. Swisher · The University of Texas MD Anderson Cancer Center4 papers (2016–2020)Jianjun Zhang · Northwestern Polytechnical University3 papers (2017–2020)Bonnie S. Glisson · The University of Texas MD Anderson Cancer Center3 papers (2017–2020)Don L. Gibbons · The University of Texas MD Anderson Cancer Center3 papers (2016–2019)Avrum Spira · Johnson & Johnson (United States)3 papers (2014–2019)David L. Rimm · Yale Cancer Center3 papers (2016–2017)Lixia Diao · The University of Texas MD Anderson Cancer Center2 papers (2018–2019)Jeffrey P. Townsend · Yale University2 papers (2016–2016)Yang Xie · Southwestern Medical Center2 papers (2014–2018)Steven M. Dubinett · APLA Health2 papers (2017–2019)F. Anthony San Lucas · The University of Texas MD Anderson Cancer Center2 papers (2017–2019)Chi‐Wan Chow · The University of Texas MD Anderson Cancer Center2 papers (2014–2016)